Evidence map›Paper›PMID 25953628›Full record

ArticleBritish journal of pharmacology2015

Activation of M3 cholinoceptors attenuates vascular injury after ischaemia/reperfusion by inhibiting the Ca2+/calmodulin-dependent protein kinase II pathway.

Xing-Zhu Lu, Xue-Yuan Bi, Xi He, Ming Zhao, Man Xu, Xiao-Jiang Yu, Zheng-Hang Zhao, Wei-Jin Zang

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. The Role of Muscarinic Acetylcholine Receptor MInternational journal of molecular sciences · 2024
    Review
  4. CaMKII as a Therapeutic Target in Cardiovascular Disease.Annual review of pharmacology and toxicology · 2023
    Review
  5. Choline supplements: An update.Frontiers in endocrinology · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Vagal nerve stimulation improves mitochondrial dynamics via an MJournal of cellular and molecular medicine · 2017
    Article
  11. Review
  12. Article
  13. Chinese innovation in cardiovascular drug discovery.British journal of pharmacology · 2015
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xing-Zhu LuDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Xue-Yuan BiDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Xi HeDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Ming ZhaoDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Man XuDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Xiao-Jiang YuDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Zheng-Hang ZhaoDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Wei-Jin ZangDepartment of Pharmacology, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe activation of M3 cholinoceptors (M3 receptors) by choline reduces cardiovascular risk, but it is unclear whether these receptors can regulate ischaemia/reperfusion (I/R)-induced vascular injury. Thus, the primary goal of the present study was to explore the effects of choline on the function of mesenteric arteries following I/R, with a major focus on Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) regulation. EXPERIMENTAL APPROACH: Rats were given choline (10 mg · kg(-1), i.v.) and then the superior mesenteric artery was occluded for 60 min (ischaemia), followed by 90 min of reperfusion. The M3 receptor antagonist, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), was injected (0.12 μg · kg(-1), i.v.) 5 min prior to choline treatment. Vascular function was examined in rings of mesenteric arteries isolated after the reperfusion procedure. Vascular superoxide anion production, CaMKII and the levels of Ca(2+)-cycling proteins were also assessed. KEY

resultsCholine treatment attenuated I/R-induced vascular dysfunction, blocked elevations in the levels of reactive oxygen species (ROS) and decreased the up-regulated expression of oxidised CaMKII and phosphorylated CaMKII. In addition, choline reversed the abnormal expression of Ca(2+)-cycling proteins, including Na(+)Ca(2+) exchanger, inositol 1,4,5-trisphosphate receptor, sarcoplasmic reticulum Ca(2+)-ATPase and phospholamban. All of these cholinergic effects of choline were abolished by 4-DAMP. CONCLUSIONS AND IMPLICATIONS: Our data suggest that inhibition of the ROS-mediated CaMKII pathway and modulation of Ca(2+)-cycling proteins may be novel mechanisms underlying choline-induced vascular protection. These results represent a significant addition to the understanding of the pharmacological roles of M3 receptors in the vasculature, providing a new therapeutic strategy for I/R-induced vascular injury.

Indexed as

Administration, IntravenousAnimalsCalcium-Calmodulin-Dependent Protein Kinase Type 2CholineCholinergic AgonistsDose-Response Relationship, DrugIschemiaMalePiperidinesRatsRats, Sprague-DawleyReceptor, Muscarinic M3Reperfusion InjurySignal TransductionStructure-Activity RelationshipVascular System Injuries4-diphenylacetoxy-1,1-dimethylpiperidiniumCalcium-Calmodulin-Dependent Protein Kinase Type 2CholineCholinergic AgonistsPiperidinesReceptor, Muscarinic M3

Identifiers

PMID25953628
PMCPMC4667848
OpenAlexW2104678731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.